{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-030396","form_type":"8-K","ticker":"NMRA","cik":"0001885522","company_name":"Neumora Therapeutics, Inc.","filed_at":"2025-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.480869+00:00","generated_at":"2026-05-25T20:51:37.361188+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Neumora modifies KOASTAL-2/-3 MDD studies, delays data to 2026; R&D head departs","bullets":["KOASTAL-2/-3 paused, resume March 2025; topline data from KOASTAL-3 in Q1 2026 and -2 in Q2 2026.","Phase 2 bipolar depression trial for navacaprant discontinued to prioritize KOASTAL program.","Robert Lenz, M.D., Ph.D., head of R&D, leaving company; will serve in advisory role.","Cash, cash equivalents and marketable securities $307.6M as of Dec 31, 2024, funding into mid-2026.","Q4 2024 net loss $58.8M vs $108.7M Q4 2023; full year net loss $243.8M vs $235.9M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-030396","json":"https://secwatch.observer/filing/0000950170-25-030396.json","markdown":"https://secwatch.observer/filing/0000950170-25-030396.md","text":"https://secwatch.observer/filing/0000950170-25-030396.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025030396/0000950170-25-030396-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025030396/nmra-20250303.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T20:51:37.361188+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}